Tradjenta Generic Name & Formulations
Linagliptin 5mg; tabs.
Dipeptidyl peptidase-4 (DPP-4) inhibitor.
Adjunct to diet and exercise in type 2 diabetes mellitus, as monotherapy or combination therapy.
Limitations of Use
Not for treatment of type 1 diabetes. Not studied in patients with a history of pancreatitis.
Tradjenta Dosage and Administration
5mg once daily.
<18yrs: not established.
Tradjenta Boxed Warnings
Consider risks/benefits in patients with known risk factors for heart failure; monitor for signs/symptoms; evaluate and consider discontinuing if develops. Monitor for signs/symptoms of pancreatitis, serious hypersensitivity reactions, severe joint pain, or bullous pemphigoid; discontinue if suspected or occurs. History of angioedema to other DPP-4 inhibitors. Pregnancy. Nursing mothers.
Antagonized by strong P-gp or CYP3A4 inducers (eg, rifampin); consider alternatives to linagliptin if used in combination. May need lower doses of the concomitant insulin secretagogue (eg, sulfonylurea) or insulin to reduce risk of hypoglycemia.
Tradjenta Adverse Reactions
Nasopharyngitis, diarrhea, cough, hypoglycemia; hypersensitivity reactions (eg, anaphylaxis, urticaria, angioedema, exfoliative skin conditions, bronchial hyperreactivity), myalgia, pancreatitis, severe and disabling arthralgia, bullous pemphigoid.
Tradjenta Clinical Trials
Tradjenta Patient Counseling